nasdaq:cmta
|
9196503
|
Feb 3rd, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
48.00
|
Open
|
Pharmaceuticals
|
Feb 2nd, 2020 09:16PM
|
Feb 2nd, 2020 09:16PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Feb 2nd, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
48.00
|
Open
|
Pharmaceuticals
|
Feb 1st, 2020 09:16PM
|
Feb 1st, 2020 09:16PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Feb 1st, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
48.00
|
Open
|
Pharmaceuticals
|
Jan 31st, 2020 09:17PM
|
Jan 31st, 2020 09:17PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 31st, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
49.00
|
Open
|
Pharmaceuticals
|
Jan 30th, 2020 09:16PM
|
Jan 30th, 2020 09:16PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 30th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
49.00
|
Open
|
Pharmaceuticals
|
Jan 29th, 2020 09:16PM
|
Jan 29th, 2020 09:16PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 29th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
49.00
|
Open
|
Pharmaceuticals
|
Jan 29th, 2020 12:03PM
|
Jan 29th, 2020 12:03PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 28th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
49.00
|
Open
|
Pharmaceuticals
|
Jan 28th, 2020 08:30AM
|
Jan 28th, 2020 08:30AM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 27th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
49.00
|
Open
|
Pharmaceuticals
|
Jan 27th, 2020 09:56AM
|
Jan 27th, 2020 09:56AM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 26th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
48.00
|
Open
|
Pharmaceuticals
|
Jan 26th, 2020 12:59PM
|
Jan 26th, 2020 12:59PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|
nasdaq:cmta
|
9196503
|
Jan 25th, 2020 12:00AM
|
Clementia Pharmaceuticals Inc.
|
1.0K
|
48.00
|
Open
|
Pharmaceuticals
|
Jan 24th, 2020 09:16PM
|
Jan 24th, 2020 09:16PM
|
Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
|
Open
|
|
Open
|
|
Montreal
|
Quebec
|
CA
|
H3B 4W5
|
|
Clementia Pharmaceuticals
|
|
|